SCHEMBL193517

SCHEMBL193517

CCCC[C@@](O)(CC)C(=O)O

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TDP1 Q9NUW8 3/20 0.44
KMT2A Q03164 2/20 0.44
L3MBTL1 Q9Y468 1/20 0.44
ALDH1A1 P00352 4/20 0.43
MAPT P10636 1/20 0.43
GAA P10253 1/20 0.39
AKR1B1 P15121 1/20 0.37
PPARG P37231 6/20 0.36
PPARD Q03181 6/20 0.36
PPARA Q07869 6/20 0.36
HDAC11 Q96DB2 5/20 0.36
TSHR P16473 4/20 0.36
GPR84 Q9NQS5 4/20 0.36
TLR2 O60603 2/20 0.36
FABP4 P15090 2/20 0.36
PTPN1 P18031 2/20 0.36
SLC22A6 Q4U2R8 1/20 0.36
SLC22A8 Q8TCC7 1/20 0.36
MEN1 O00255 1/20 0.36
ESR1 P03372 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL381230 1.00 TDP1 (0.44) TDP1KMT2AL3MBTL1ALDH1A1MAPT
Undecane SCHEMBL28372274 0.96 GPR84 (0.43) TDP1KMT2AL3MBTL1ALDH1A1PPARG
SCHEMBL380743 0.93 GAA (0.45) TDP1KMT2AL3MBTL1ALDH1A1GAA
SCHEMBL9084120 0.92 KMT2A (0.40) TDP1KMT2AL3MBTL1ALDH1A1MAPT
SCHEMBL3294519 0.91 FDPS (0.45) TDP1KMT2AALDH1A1GAAPPARG
SCHEMBL380519 0.91 FDPS (0.45) TDP1KMT2AALDH1A1GAAPPARG
SCHEMBL8376531 0.91 FDPS (0.45) TDP1KMT2AALDH1A1GAAPPARG
SCHEMBL9633625 0.91 FDPS (0.45) TDP1KMT2AALDH1A1GAAPPARG
SCHEMBL3918719 0.91 FDPS (0.45) TDP1KMT2AALDH1A1GAAPPARG
SCHEMBL165415 0.91 FDPS (0.45) TDP1KMT2AALDH1A1GAAPPARG

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1908747-B1 PROCESS FOR PRODUCING OPTICALLY ACTIVE 2-HYDROXYBUTYRIC ESTER KOWA CO (JP) 2012-01-04 EP disclosed
US-7767845-B2 reacting an optically active 2,3-epoxypropionic ester with a methyl Grignard reagent CH3MgX in the presence of a copper catalyst in an amount of 0.05 to 0.5 mol with respect to 1 mol of the 2,3-epoxypropionic ester; for producing pharmaceuticals, pesticides, and industrial products KOWA CO., LTD. (JP) 2010-08-03 US disclosed
US-7582791-B2 Process for producing optically active ester KOWA CO., LTD. (JP) 2009-09-01 US disclosed
US-20090209780-A1 reacting an optically active 2,3-epoxypropionic ester with a methyl Grignard reagent CH3MgX in the presence of a copper catalyst in an amount of 0.05 to 0.5 mol with respect to 1 mol of the 2,3-epoxypropionic ester; for producing pharmaceuticals, pesticides, and industrial products KOWA CO., LTD. (JP) 2009-08-20 US disclosed
US-20090118535-A1 PROCESS FOR PRODUCING OPTICALLY ACTIVE ESTER KOWA CO., LTD. (JP) 2009-05-07 US disclosed
US-4060691-A 7-{3-Hydroxy-2-[4-hydroxy-4-(lower alkyl)-trans-1-octen-1-yl]-5-oxocyclopent-1-yl}heptanoic acids and esters G. D. SEARLE & CO. (US) 1977-11-29 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090118535-A1 PROCESS FOR PRODUCING OPTICALLY ACTIVE ESTER CYP8B1, HACL2, ACSL3 TDP1 4528/4885KMT2A 4285/4885L3MBTL1 1914/4885
US-20090209780-A1 reacting an optically active 2,3-epoxypropionic ester with a methyl Grignard reagent CH3MgX in the presence of a copper catalyst in an amount of 0.05 to 0.5 mol with respect to 1 mol of the 2,3-epoxypropionic ester; for producing pharmaceuticals, pesticides, and industrial products CYP4X1, AGL, HACL2 TDP1 4594/4885KMT2A 1229/4885L3MBTL1 729/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.